ClinicalTrials.gg
CompletedNCT06508606Updated Oct 15, 2026

AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of AK117 + Cetuximab in Head and Neck Squamous Cell Carcinoma, sponsored by West China Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by West China Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 15, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
81st of 84
10 · median 46
Started
2024
with 2 others
Phase 2
41 of 86
6 open now
Registered
75th of 86
by date

Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 81st largest by enrollment of the 84 interventional ones that give a count, is one of 3 that started in 2024, is one of 41 in phase 2, and was the 75th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

The administration of first-line pembrolizumab monotherapy or combined chemotherapy has been shown to improve survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, over 80% of the patients still experience disease progression within a year. Upon progression, treatment options are notably constrained, typically comprising methotrexate, docetaxel, and cetuximab. The median progression-free survivaland overall survival following chemotherapy, targeted therapy, or their combination are dismally low, ranging from 2-3 months and 6-8 months, respectively. The clinical trials CheckMate 141 and KEYNOTE 040 have led to the approval of Nivolumab and Pembrolizumab as second-line treatments for R/M HNSCC. Nevertheless, the response rates to immune monotherapy are limited, ranging from 10% to 35%. Even after receiving standard second-line immunotherapy, over 80% of patients encounter disease progression within 6 months, and more than 60% succumb to the disease within a year. Therefore, there is a dearth of a standardized treatment for R/M HNSCC after the failure of first- or second-line PD-1 (L1) inhibitors and/or platinum-based therapy

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed R/M HNSCC (including oral, oropharyngeal, hypopharyngeal, and laryngeal sites); Recurrence that cannot be cured by local treatment, and previous treatment with (L1) inhibitors and/or platinum-based chemotherapy has failed.
  2. At least one according to v1.1, excluding previously irradiated lesions unless clear progression occurred more than 3 months after the last radiotherapy;
  3. Known HPV p16 status of oropharyngeal cancer;
  4. Known PD-L1 expression status;
  5. performance status of 0-1;
  6. Expected survival ≥ 3 months;
  7. Adequate bone marrow function, defined as: ≥ 9.0 g/dL (90 g/L); ≥ 1,500/mcL (1.5 × 10\^9/L); ≥ 100,000/mcL (100 × 10\^9/L) and no blood transfusion within 3 weeks or growth factor (G-CSF, EPO) therapy within 2 weeks prior to dosing;
  8. Adequate liver function, defined as: ≤ 1.5× (ULN); If no liver , and ALT ≤ 2.5× ULN; if liver metastases are present, AST or ALT ≤ 3.0× ULN; ALP ≤ 1.5× ULN; if liver metastases ≤ 2× ULN; Serum albumin ≥ 30g/L;
  9. Adequate coagulation function: or PT, APTT ≤ 1.5× ULN. Participants on anticoagulant therapy should have these laboratory indices closely monitored;
  10. Adequate renal function, defined as creatinine ≤ 1.5× ULN or Ccr ≥ 50 mL/min calculated using the formula corrected for body surface area;
  11. Baseline (LVEF) ≥ 50% measured by multiple-gated acquisition (MUGA) or echocardiogram (ECHO);
  12. No severe organic heart disease or arrhythmias;
  13. Women of (aged 15-49 years) must have a negative pregnancy test within 7 days before starting treatment. Both male and female participants of must agree to use effective measures during the study period and for 3 months after discontinuation of treatment;
  14. Voluntary signed by the study participant.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have received treatment with cetuximab in the .
  2. Grade ≥2 peripheral neuropathy (according to 5.0).
  3. Anticipated need for surgery or any other form of systemic or local anti-tumor therapy during the study, including maintenance therapy or radiotherapy for head and neck squamous cell carcinoma (excluding palliative treatment for non-target lesions).
  4. Received systemic chemotherapy within 3 weeks prior to first administration of study drug, received small molecule targeted therapy within 2 weeks prior to first administration or within 5 half-lives (whichever is longer), received anti-tumor biologic therapy, large molecule targeted therapy or immunotherapy within 4 weeks prior to first administration, or underwent major surgery (excluding minor surgery within 2 weeks with complete recovery); received radiotherapy within 14 days prior to first administration of study drug (excluding central nervous system radiotherapy which requires a of ≥28 days).
  5. Known active central nervous system and/or carcinomatous meningitis. Participants with treated may participate if stable, without progressive or new neurological deficits, seizures, evidence of increased intracranial pressure, vomiting, or headaches.
  6. Lesions that are superficially ulcerated or have broken through at baseline.
  7. Residual toxicity from prior anti-tumor therapy (excluding alopecia, fatigue, and grade 2 hypothyroidism) or laboratory abnormalities > grade 1 (CTCAE v5.0).
  8. Pulmonary embolism or deep vein thrombosis within 3 months prior to first administration of study drug.
  9. Known history of malignant tumors.
  10. Any severe or uncontrolled systemic disease, including poorly controlled hypertension, diabetes.
  11. History of active bleeding, coagulation disorder, or participants receiving coumarin anticoagulant therapy.
  12. Known active or . Active hepatitis B is defined as known HBsAg positive and HBV DNA ≥500 IU/mL.
  13. Concurrent severe, uncontrolled infections or known (HIV) (HIV antibody positive) infection, or diagnosis of acquired immune deficiency syndrome (AIDS); or poorly controlled disease; or history of allogeneic tissue/organ transplant, stem cell or bone marrow transplant, or prior solid organ transplant.
  14. Active bacterial, viral, fungal, rickettsial, or parasitic infections requiring systemic anti-infective therapy (unless treated and resolved before administration of study drug).
  15. Received within 30 days prior to first administration of study drug. Use of inactivated seasonal influenza vaccine or approved COVID-19 vaccine is allowed, with a washout period of >1 week prior to first administration of study drug.
  16. History of or concurrent interstitial pneumonia, severe with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm.
  17. Received immunological therapy for any reason, including long-term use equivalent to >10 mg/day prednisone within 7 days prior to first administration of study drug or at any time during the study.
  18. Uncontrolled pleural, peritoneal, pelvic effusion, or pericardial effusion requiring drainage ≥1 time per month.
  19. Pregnancy test positive or breastfeeding participants. Women and men participants who do not plan to take adequate measures within 180 days after the end of treatment.
  20. Any other disease or clinically significant laboratory parameter abnormalities, severe medical or psychiatric condition, including substance abuse including alcohol abuse, which the investigator believes may compromise the safety of the participant, the integrity of the study, participant's ability to participate in the study, or interfere with the study objectives and result analysis.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    AK117+Cetuximab

    Patients meeting the inclusion criteria were given AK117 45mg/kg (D1, IVGTT, Q3W) in combination with Cetuximab (initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained until progression or intolerable toxicity occurred

    Drug: AK117 + Cetuximab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients with Adverse Events (AEs)

    Characterization of incidence, severity and abnormal clinically significant laboratory findings of AEs

    Time frame: Up to approximately 1 years

  2. OS

    overall survival

    Time frame: Up to approximately 1 years

Secondary outcomes

  1. ORR

    Objective response rate

    Time frame: Up to approximately 1 years

  2. PFS

    Progression Free Survival

    Time frame: Up to approximately 1 years

  3. DCR

    Disease control rate

    Time frame: Up to approximately 1 years

  4. DoR

    Duration of Response

    Time frame: Up to approximately 1 years

07

Study locations

1 site
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2026, 24 months.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 24 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Nov 2026 → Aug 2026 and completion Aug 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2024
First posted
Jul 18, 2024
StartActual
Aug 1, 2024
Primary completionActual
Aug 1, 2026was Nov 2026
CompletionActual
Aug 1, 2026was Aug 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Primary completion
Nov 1, 2026→Aug 1, 2026 (actual)
Oct 15, 2026
Study completion
Aug 1, 2027→Aug 1, 2026 (actual)
Oct 15, 2026
Enrollment
20 (estimated)→10 (actual)
Oct 15, 2026
Interventions
Removed Drug: AK117 + AK104. Arms removed: AK117+AK104
Oct 15, 2026
Title
AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Completed
    Primary completion Nov 1, 2026→Aug 1, 2026 (now actual)
    Study completion Aug 1, 2027→Aug 1, 2026 (now actual)
    Enrollment 20 (estimated)→10 (actual)
    Interventions Removed Drug: AK117 + AK104. Arms removed: AK117+AK104
    Title AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    + 1 other change: design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06508606
Responsible party
Lei Liu (professor, West China Hospital) — Principal investigator
First posted
Jul 18, 2024
Start date
Aug 1, 2024
Primary completion
Aug 1, 2026
Completion
Aug 1, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ligufalimab · Cetuximab

Start the discussion